GlassScriptPhysician profile
Dinar Sajan
NPI 1659536027
$19,217.92
in general payments reported to CMS, 2019-2025
34 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $1,376 · 2021: $1,918 · 2022: $4,161 · 2023: $4,888 · 2024: $2,694 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,006.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,517.17 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $3,169.06 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,656.41 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,606.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $965.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $871.38 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $863.53 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $856.64 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $844.31 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $771.02 | 2020-2024 | Hetlioz, Fanapt |
| Lundbeck LLC | $708.50 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $531.51 | 2019-2022 | |
| Neuronetics, INC. | $405.76 | 2019-2025 | Neurostar Tms Therapy System |
| E.R. Squibb & Sons, L.L.C. | $283.25 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $196.77 | 2022-2025 | Auvelity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $185.53 | 2019-2024 | Perseris |
| Eisai INC. | $127.45 | 2020-2021 | |
| Almatica Pharma LLC | $112.06 | 2022-2024 | Loreev Xr, Gralise |
| Sage Therapeutics, LLC | $70.21 | 2023-2024 | |
| Noven Therapeutics, LLC | $66.96 | 2024-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $51.95 | 2022-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $49.76 | 2022-2023 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $40.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $36.17 | 2019 | |
| Medtronic, INC. | $33.34 | 2023 | Intellis Adaptivestim |
| Avanir Pharmaceuticals, INC. | $29.80 | 2019-2020 | |
| Bausch Health US, LLC | $29.25 | 2022 | |
| Corium, LLC | $25.80 | 2023 | Azstarys |
| Alfasigma USA, INC. | $22.70 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.96 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.10 | 2019 | |
| Boston Scientific Corporation | $18.70 | 2023 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $16.53 | 2023 | Quviviq |
| Shire North American Group INC | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinar Sajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.